Whether you are a researcher or clinician working in a field related to rare diseases, the Orphanet Journal of Rare Diseases is a great resource to keep abreast of current research. It covers rare diseases and orphan drugs and features a peer-review system, impact score, and article processing charges.
Abbreviation
Generally speaking, the abbreviation of Orphanet journal of rare diseases is OJRD. It is the official journal of the Orphanet. This journal covers all aspects of rare diseases, including genetic counselling and diagnosis. The journal publishes reviews, case reports, and letters to the editor. In addition, it focuses on the latest developments in diagnosis and treatment.
Conference Proceedings are short summaries of findings presented at important scientific meetings. These findings provide an early view of current research. This may include findings from recent clinical trials. Similarly, a case report is a descriptive study of a single individual. The case report usually describes a case in which a patient has been diagnosed, accompanied by diagnostic studies and a treatment course.
Impact score
Among all the dozens of journals available in the health care arena, the Orphanet Journal of Rare Diseases stands out as one of the most notable. This journal focuses on the state of the art developments in the field of rare diseases, with particular emphasis on the clinical aspects of rare disease, genetic counselling, and aetiopathogenesis. In addition, it also considers results of clinical trials of exceptional interest.
The Orphanet Journal of Rare Diseases is a peer-reviewed, open-access journal. It is published by BioMed Central Ltd., a company located in the United Kingdom. In addition to the journal, the company produces a free twice-monthly newsletter, OrphaNews. These resources provide readers with an overview of the latest in rare disease news, as well as an opportunity to contribute.
Peer-review system
Using a peer-review system for Orphanet Journal of Rare Diseases helps to maintain high quality review articles and allows the public to access them online. The Orphanet database provides access to more than 400 rare diseases and includes clinical guidelines, genetic counseling, and clinical work-ups. Using a system of independent researchers, the submitted manuscripts are assessed for quality and significance.
Rare diseases are a group of diseases that affect a large number of people. They are often genetic in origin and often life-threatening. Typically, they affect children and newborns.
Clinical guidelines are designed to encode evidence-based recommendations for clinical care. They are developed by health technology assessment (HTA) agencies, learned societies, and other organizations. They are designed to help the health care professionals make important decisions. They are a valuable resource for patients and their families.
Article processing charges
Whether you are a researcher, doctor or patient you can find interesting articles about rare diseases in the Orphanet Journal of Rare Diseases. This is a free online resource that offers readers the latest news, reviews and scientific research related to rare diseases and their treatments. In addition to articles, the Orphanet also has a free twice monthly newsletter.
The Orphanet Journal of Rare Diseases was founded in 2006 and is published by BioMed Central. The journal covers all aspects of rare diseases including clinical work-up, genetic counseling, and more. The journal’s open-access policy means that all articles are freely accessible online, and there are no copyright tyrannies.
Coverage of rare diseases and orphan drugs
Various policy initiatives and regulatory schemes exist for orphan medicines. These include orphan designations, accelerated market approval, tax incentives and free scientific advice. They are all part of the larger effort to address the unmet need of orphan diseases. However, despite the growing number of orphan drug approvals, there is still concern that they may be unaffordable.
The US Food and Drug Administration (FDA) has approved hundreds of drugs for rare diseases since 1983. Although these drugs have improved patient quality of life, their prices are often out of reach. In addition, the success of orphan drugs has created financial strain on health systems.
Letter to the editor
Having a rare disease can be very stressful for parents, particularly when it is first detected. They often feel confused, helpless and isolated. They may turn to alternative medicine for support, lose hope in the conventional healthcare system or seek a second opinion.
In this letter to the editor, the authors call for more effective collaboration between the health and social care sector and the rare disease community. They identify four priorities for improving rare disease care in the next five years.
One of the key priorities identified is the timing of diagnosis. The authors point out that delays in diagnosis can lead to alterations in treatment options. They also highlight the importance of better coordination of care.
